Deepa Jeyakumar, M.D. Assistant Clinical Professor, Division of Hematology/Oncology At University of California Irvine Discusses Three New Drugs Approved For…
Browsing: Acute Myelogenous Leukemia
Deepa Jeyakumar, M.D. Assistant Clinical Professor, Division of Hematology/Oncology At University of California Irvine Discusses Dosing Regarding Venetoclax. At MOASC…
Deepa Jeyakumar, M.D. Assistant Clinical Professor, Division of Hematology/Oncology At University of California Irvine Discusses Can Glasdegib Be Used As…
Samer Khaled, MD, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses Incorporating Venetoclax Into…
Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Molecular…
John Burke, MD, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Beat…
John Burke, MD, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Gilteritinib…
Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses The Rationale For Genetically Profiling…
Keith Pratz, MD, Assistant Professor of Oncology, Sidney Kimmel, Comprehensive Cancer Center, Johns Hopkins University, Discusses Phase I Study Of…
Keith Pratz, MD, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses Reliability Of The Companion…
James McCloskey, MD, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses Molecular Testing In…
John Burke, MD, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Incorporation…
James McCloskey, MD, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses How The FLT3…
Keith Pratz, MD Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses Emerging Therapies For Newly…
Keith Pratz, MD, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses Venetoclax In Treatment Of…
John Burke, MD Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Reliability…
Keith Pratz, MD Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses How Gilteritinib Fits Into…
James McCloskey, MD Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses The Role Of…
Samer Khaled, MD Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Discusses Treatment Of Acute…
John Burke, MD Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers Discusses Research…
James McCloskey, MD Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center Discusses Application Of The…
Keith Pratz, MD Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Discusses AML Genetic Testing Prior…
Edward Copelan, MD Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute Discusses Gilteritinib For Patients With FLT3+…
Earn CME: https://naccme.com/program/7311 In this presentation from the ‘FLT3 Targets in RIn this presentation from the ‘R AML: Evaluating Emerging…
Earn CME: https://naccme.com/program/7311 In this presentation from the ‘FLT3 Targets in RIn this presentation from the ‘R AML: Evaluating Emerging…
Earn CME: https://naccme.com/program/7311 In this presentation from the ‘FLT3 Targets in AML: Evaluating Emerging Clinical Data and Implications on Current…
Earn CME: https://naccme.com/program/7311 In this presentation from the ‘FLT3 Targets in AML: Evaluating Emerging Clinical Data and Implications on Current…
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, talks about the collective organizational efforts to…
While novel FLT3 inhibitors have been, or will be, approved for use as single agents in the treatment of acute…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, Alexander Perl, MD, of the…
Venetoclax in combination with low intensity chemotherapy for acute myeloid leukemia (AML) in the frontline setting, which although currently under…
Despite benefits of targeted therapies for genetic mutations in AML, a limitation with this approach is that the mutation may…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Harry Erba of Duke University, Durham,…
From the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Harry Erba of Duke University, Durham, NC,…
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Srdan Verstovsek, MD, PhD, from the MD Anderson Cancer…
In this interview, Prof. Srdan Verstovsek, MD, PhD, from the MD Anderson Cancer Center, Houston, TX, suggests that various parameters…
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Srdan Verstovsek, MD, PhD, from the MD Anderson Cancer…
Myeloproliferative neoplasms, a group of blood disorders, have debilitating effects on patients, including shortening life expectancy and lowering the quality…
Currently, out of all FLT3 inhibitors, only midostaurin is FDA-approved for use in patients with acute myeloid lymphoma (AML). From…
The IDH1 and IDH2 metabolic enzymes are mutated in patients with acute myeloid leukemia (AML), prompting the pharmaceutical development of…
In the last 15 years, there has been a revolution in our understanding of the pathogenesis of acute myeloid lymphoma…
Venetoclax monotherapy has yielded disappointing results in acute myeloid leukemia (AML) because resistance develops along with the propagation of MCL1-expressing…
Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the effectiveness of drugs currently on the market to…
While venetoclax is widely used in chronic lymphocytic leukemia (CLL) to good effect, previous studies have suggested that the drug…
At the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, Alexander Perl, MD, of the University…
Christopher Gibson, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the multiple uses of next-generation sequencing (NGS) in the management…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, Christopher Gibson, MD, of Dana-Farber…
DNA sequencing approaches such as next-generation sequencing (NGS) have been found to be particularly useful when diagnosing cancers. These results…
Christopher Gibson, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the reliability of next-generation sequencing (NGS) at the 2018 Society…
Florent Malard, MD, PhD, of Saint Antoine Hospital, Paris, France, discusses potential measures to improve the outcome of transplantation at…